Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 21, 2014
Pharmacy Choice - Pharmacy News - November 21, 2014

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
11/21/14 - Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture;...
SUMMARY: The Food and Drug Administration is announcing the availability of a document entitled "Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture; Guidance for Industry" dated December 2014. The guidance announced in this notice finalizes the draft guidance
11/20/14 - AZE Technology, Inc. Announces FDA Approval of Phoenix (Volume Registration Viewer)
--AZE Technology today announces the U.S. Food and Drug Administration approval of Phoenix, a viewer developed with a completely new concept for efficient and accurate image interpretation. Phoenix is designed with background volume-processing performed at the same time as data input, and presents various dramatic outcomes that were not possible wi
11/20/14 - FDA Approves Extended-Release, Single-Entity Hydrocodone Product With Abuse-Deterrent Properties
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. The FDA has determined that the physical and chemical properties of Hysingla ER are expected to make abuse by these routes difficult. "While the science of abuse deterrence is still evolving, the development of opioids that are harder
11/20/14 - FDA approves new, hard-to-abuse hydrocodone pill
The Food and Drug Administration approved Purdue Pharma's Hysingla ER, for patients with severe, round-the-clock pain that cannot be managed with other treatments. Purdue Pharma's new drug poses a direct commercial challenge to Zogenix's much-debated drug Zohydro, a twice-a-day hydrocodone tablet approved by the FDA last year. The FDA has been unde
11/20/14 - JCI Pharmaceutical Co., Ltd. Receives Approval from US FDA for Colloidal Iodine Formulation
Tokyo, Nov 20, 2014-- JCI Pharmaceutical Co., Ltd. has announced approval by the US FDA for its MN colloid iodine, a formulation utilizing a world-first technology for converting iodine into a colloidal state to make it absorbable into the body at a large doses. The new formulation converts iodine into a colloid state and further processes it to ma
11/20/14 - Kubtec® Announces FDA Approval of the Highest Resolution Low Dose Portable Digital Radiography System for NICU
--Kubtec, the foremost developer of low dose digital radiography systems, today announced FDA approval of the KUB 250, the first truly portable low-dose digital X-ray system dedicated to the neonatal intensive care unit. "The KUB 250 has been clinically tested to reduce radiation exposure by up to 40% with our advanced high resolution imaging tech

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
HIV & AIDS Testing & Reporting Guidelines
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement